Stonnington Group LLC raised its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 29.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 30,788 shares of the company’s stock after acquiring an additional 6,949 shares during the period. Johnson & Johnson makes up 1.5% of Stonnington Group LLC’s investment portfolio, making the stock its 14th largest holding. Stonnington Group LLC’s holdings in Johnson & Johnson were worth $5,496,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in JNJ. Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $4,172,929,000. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. GQG Partners LLC increased its holdings in Johnson & Johnson by 1,109.4% during the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after acquiring an additional 3,627,424 shares in the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after acquiring an additional 3,358,478 shares in the last quarter. Finally, State Street Corp increased its holdings in Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the stock. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. UBS Group decreased their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Citigroup decreased their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, SVB Leerink decreased their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $189.78.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.
Johnson & Johnson announced that its board has authorized a stock repurchase program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.